Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Director Gary Ng Wang Yu of Niagen Bioscience (NAGE) was granted stock options on June 24, 2025. The key details of this Form 4 filing include:
- Received 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- Options will vest 100% on June 24, 2026
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule suggests a standard annual director equity award structure. The 10-year exercise period from the grant date provides long-term alignment with shareholder interests.
Form 4 filing reveals that Ann Cohen, Director at Niagen Bioscience, was granted stock options on June 24, 2025. Key details of the transaction:
- Received 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- Options will vest 100% on June 24, 2026
- Options expire on June 23, 2035
- Direct ownership form of securities
This grant represents a standard director compensation package, with a one-year cliff vesting schedule. The filing was signed by James Lee as attorney-in-fact on June 25, 2025. No other securities transactions were reported in this filing.
Form 4 filing reveals that Frank L. Jaksch Jr., Director of Niagen Bioscience (NAGE), was granted 20,000 stock options on June 24, 2025. The options have the following key terms:
- Exercise price set at $14.13 per share
- Options will vest fully (100%) on June 24, 2026
- Expiration date is June 23, 2035
- Underlying security is Common Stock
The transaction was reported through an attorney-in-fact, James Lee Jeong, and filed on June 25, 2025. This grant represents a new position in derivative securities for the director, with direct beneficial ownership of all 20,000 options. The filing indicates standard compensation practices for board members through equity-based incentives.